NCT04073459UnknownPhase 2
A Multi-center, Randomized, Active-controlled, Parallel-group, Open-label and Phase II Study to Evaluate Immunogenicity and Safety of LBVD (Fully Liquid Hexavalent Vaccine; Adsorbed Diphtheria-Tetanus-Pertussis-Hepatitis B- Inactivated Poliomyelitis (Sabin) and Haemophilus Influenzae Type b Conjugate Vaccine) Compared to Co-administration of EupentaTM Inj. and Imovax® Polio (Poliomyelitis Vaccine (Inactivated)) in Separate Injections in Healthy Infants at 6-10-14 Weeks of Age as Primary Series
LG Chem0 sites336 target enrollmentStarted: November 1, 2019Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Enrollment
- 336
- Primary Endpoint
- seroprotection/seroconversion/vaccine-response rate
Study Overview
Brief Summary
The purpose of the study is to evaluate immunogenicity and safety of three different doses of candidate hexvalent vaccine in comparison to co-administration of EupentaTM Inj. and Imovax® Polio in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants and thereby to select the optimal dose of candidate vaccine
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 6 Weeks to 8 Weeks (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •A male or female healthy (i.e. free of obvious health problems) infant who have reached at least 42 days (6 weeks) of age and not more than 56 days (8 weeks) of age at the time of first vaccination
- •Born at full term pregnancy (Gestational age ≥ 37 weeks)
- •Body weight ≥ 3.2 kg at the time of screening
- •Received one dose of hepatitis B mono-vaccine within seven days of birth
- •Born to both hepatitis B virus surface antigen (HBsAg) and human immunodeficiency virus (HIV) negative mother
- •Subject's parent(s) or Legally Acceptable Representative (LAR) able to understand and comply with planned study procedures
- •Written informed consent by subject's parent(s) or LAR
Exclusion Criteria
- •Previously received any dose of diphtheria, tetanus, pertussis, polio and/or Hib containing vaccines
- •History of previous or concurrent vaccinations other than hepatitis B, Bacillus Calmette-Guerin (BCG), rotavirus and pneumococcal vaccine
- •Known or suspected history of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, or Hib diseases
- •Household contact and/or intimate exposure in the previous 30 days to an individual with ascertained diphtheria, pertussis, hepatitis B, polio or Hib diseases
- •Experienced fever ≥ 38°C (100.4°F) within the past three days prior to screening
- •Experienced significant acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the past seven days prior to screening
- •Known or suspected immune disorder or immunodeficient condition
- •Receipt of immunoglobulin or blood-derived product since birth
- •Chronic administration (defined as more than 14 days) of immunosuppressant or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone, or equivalent, ≥0.5mg/kg/day. Inhaled and topical steroids are allowed.
- •History of bleeding disorder contraindicating intramuscular injection
- •Major congenital defects or serious chronic illness
- •History of any neurological disorders or seizures
- •History of allergic reactions to any vaccine components including excipients and preservatives (neomycin, streptomycin, polymyxin B, yeast or etc.)
- •History of allergic reactions to latex
- •Participation in another interventional trial or received any investigational product within 30 days before to the enrollment
- •Plan to leave the area of the study site before the end of the study period
- •Infants who are considered unsuitable for the clinical study by the investigator
Arms & Interventions
Pentavalent+IPV
Active Comparator
Co-administration of EupentaTM Inj and Imovax Polio
Intervention: Pentavalent vaccine and Salk IPV (Biological)
H dose of Hexavalent
Experimental
High dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib).
Intervention: DTwP-HepB-Sabin IPV-Hib (Biological)
L dose of Hexavalent
Experimental
Low dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
Intervention: DTwP-HepB-Sabin IPV-Hib (Biological)
M dose of Hexavalent
Experimental
Middle dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
Intervention: DTwP-HepB-Sabin IPV-Hib (Biological)
Outcomes
Primary Outcomes
seroprotection/seroconversion/vaccine-response rate
Time Frame: 4 weeks after three-dose primary series
Proportion of subjects achieving seroprotection/seroconversion/vaccine-response to each antigenic components
Secondary Outcomes
- Seroprotetion rate against PRP with cut-off ≥ 1 µg/mL(4 weeks after three-dose primary series)
- Geometric mean concentration (GMC) or Geometric mean titer (GMT)(4 weeks after three-dose primary series)
- Seroprotection rate against diphtheria with cut-off ≥ 1.0 IU/mL(4 weeks after three-dose primary series)
- Seroprotection rate against tetanus with cut-off ≥ 1.0 IU/mL(4 weeks after three-dose primary series)
- Seroconversion rate against Salk serotypes(4 weeks after three-dose primary series)
- Seroprotection rate against Sabin and Salk serotypes(4 weeks after three-dose primary series)
Investigators
Similar Trials
Completed
Phase 2
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.Tick-borne EncephalitisNCT00161798Pfizer
Completed
Phase 2
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.Tick-borne EncephalitisNCT00161772Pfizer
Completed
Phase 3
Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio VaccinePoliomyelitisNCT04386707Sinovac Biotech Co., Ltd1,300
Withdrawn
Phase 1
Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously ImmunizedCovid19NCT05016934Hospital do Coracao
Completed
Phase 2
Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005InfluenzaNCT00161811Alachua Government Services, Inc.1,400